Clinical trials: Spondylitis, Ankylosing
Ankylosing Spondylitis
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.
- Trial name
- ONSET (NCT06905288)
- Testing
- Secukinumab
- Where
- 3 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Axial Spondyloarthritis
Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis
The objective of this multicenter, randomized, double-blind study was to evaluate the efficacy and safety of continuing versus withdrawing therapy with adalimumab 40 mg given every other week SC in maintaining remission in…
- Trial name
- NCT01808118
- Testing
- adalimumab
- Volunteers
- 673 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
This study assessed the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to secukinumab and evaluated to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be…
- Trial name
- ASTRUM (NCT02763046)
- Testing
- Secukinumab (AIN457) 150 mg s.c.
- Where
- 39 sites in Germany
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
- Trial name
- MEASURE 1 (NCT01358175)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 67 sites in United States, Belgium and 12 more
- Volunteers
- 371 people
- Sponsor
- Novartis Pharmaceuticals
Spondyloarthritis
A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).
- Trial name
- NCT04285229
- Testing
- Ixekizumab
- Where
- 19 sites in China
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Ankylosing Spondylitis
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)
This study is the trial to demonstrate how our product is similar to remicade by comparing the results of blood samples in active Ankylosing Spondylitis patients.
- Trial name
- NCT01220518
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 257 people
- Sponsor
- Celltrion
Spondylitis, Ankylosing
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.
- Trial name
- RE-EMBARK (NCT02509026)
- Testing
- Etanercept
- Where
- 82 sites in United States, Australia and 12 more
- Volunteers
- 210 people
- Sponsor
- Pfizer
Osteoarthritis, Rheumatoid Arthritis
Observational Study on Non-steroid Anti-inflammatory Drugs (NSAIDs) Treated Patients With Arthritic Disorder
The aim of this study is to find out how patients with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis receiving NSAID-therapy are treated and managed by their doctor in usual clinical practice, how patients…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EVIDENCE (NCT01176682)
- Where
- 244 sites in Belgium, France and 10 more
- Volunteers
- 1,149 people
- Sponsor
- AstraZeneca
Spondylarthritis, Psoriatic Arthritis
A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
The objective of this study is to access retention rate, persistence and adherence in population of spondylarthritis (SpA) (ankylosing spondylitis (AS) and psoriatic arthritis (PsA)) participants treated with adalimumab in…
- Conditions
- Spondylarthritis, Psoriatic Arthritis, Ankylosing Spondylitis (AS)
- Trial name
- Adherence (NCT02988674)
- Where
- 14 sites in Russia
- Volunteers
- 139 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis
- Trial name
- NCT04840485
- Testing
- SHR-1314
- Where
- China
- Volunteers
- 548 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Osteoarthritis (OA), Rheumatoid Arthritis (RA)
Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).
RATIONAL is a multinational, multicentre, observational, cross sectional study of adult patients in treatment with NSAID therapy for OA, RA or AS during for at least 2 weeks before study visit (at least one dose).
- Conditions
- Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS)
- Trial name
- RATIONAL (NCT01577563)
- Where
- 85 sites in Argentina, Colombia and 8 more
- Volunteers
- 5,383 people
- Sponsor
- AstraZeneca
Ankylosing Spondylitis
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
This is a multi-center, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of ENIA11 in patients with ankylosing spondylitis.
- Trial name
- NCT02685904
- Testing
- ENIA11
- Where
- 6 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Mycenax Biotech Inc.
Rheumatoid Arthritis, Ankylosing Spondylitis
bIosimilar of aDalimumab, an European evAluation
The study objective is aimed to describe all country, site, investigator and patient variables that lead to treatment persistence for at least 12 months among patients with rheumatologic and intestinal chronic inflammatory…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn Disease
- Trial name
- IDEA (NCT05190484)
- Volunteers
- 1,050 people
- Sponsor
- Fresenius Kabi
Ankylosing Spondylitis
Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)
The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.
- Trial name
- NCT01079182
- Volunteers
- 4,681 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ankylosing Spondylitis
Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
The purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of Ankylosing Spondylitis.
- Trial name
- NCT00247962
- Testing
- etanercept, sulphasalazine (SSZ)
- Where
- 83 sites in Australia, Austria and 16 more
- Volunteers
- 566 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Efficacy and Safety Study of SUNPG1622
This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
- Trial name
- NCT02980705
- Testing
- SUNPG1622 I dose
- Where
- 4 sites in United States, Hungary and 2 more
- Volunteers
- 180 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Ankylosing Spondylitis
Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
Primary objective: to evaluate the efficacy of Sarilumab in participants with Ankylosing Spondylitis (AS) using the assessment in AS working group criteria (ASAS) 20% response criteria (ASAS20) Secondary objectives: to…
- Trial name
- ALIGN (NCT01061723)
- Testing
- Sarilumab
- Where
- 80 sites in United States, Australia and 12 more
- Volunteers
- 301 people
- Sponsor
- Sanofi
Spondylitis, Ankylosing
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in patients with ankylosing spondylitis (AS) who had an inadequate response to previous tumor necrosis…
- Trial name
- NCT01209689
- Testing
- Tocilizumab
- Where
- 140 sites in United States, Australia and 17 more
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Ankylosing Spondylitis
Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis
The objective of this observational study is to determine the incidence of response in patients with predictive factors of major clinical response in active ankylosing spondylitis (AS) in patients who start anti-tumor necrosis…
- Trial name
- PRETEA (NCT00900796)
- Testing
- Treatment switching
- Where
- Spain
- Volunteers
- 132 people
- Sponsor
- Pfizer
Ankylosing Spondylitis, Psoriatic Arthritis
Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
This observational study will document to what extent in daily clinical practice the work productivity is affected before and after the start of adalimumab treatment.
- Trial name
- SPACTIVE (NCT01845818)
- Volunteers
- 183 people
- Sponsor
- AbbVie